Dr. Thierry Dubois

Breast Cancer Biology Group, France

Email: [email protected]

Qualifications

1995 Ph.D., University of Paris 6, Molecular and Cellular Pharmacology

Publications (selected)

1. Gomez‐Duro, M., Bergam, P., Sanchez‐Redondo, S., et al. (2026). CD133 Shapes Extracellular Vesicle Cargo and Angiogenic Function in Basal‐Like Triple‐Negative Breast Cancer. Journal of Extracellular Vesicles, 15(6), Article e70303.
2. Shechter, D., Huang, R., Shah, P., et al. (2026). Meeting report on FASEB protein arginine methylation: mechanism to therapeutics. Journal of Biological Chemistry, Article 111448. Advance online publication.
3. García-Areas, R., Girard, E., Lasla, H., et al. (2026). Wnt signaling promotes inflammation and EMT-associated gene expression in mesenchymal TNBC. Scientific Reports, 16, Article 5678.
4. Cogoluegnes, S., Kovachka, S., Dubois, T., et al. (2025). Inhibition of PTCH1 drug efflux activity enhances chemotherapy efficacy against triple negative breast cancer. bioRxiv. Advance online publication.
5. Huard, S., Suresh, S., Vayr, J., et al. (2025). CARM1-mediated methylation controls interactions of ALIX with key partners important for cytokinesis. bioRxiv. Advance online publication.
6. Bos, I., Amiri, S., Maire, V., et al. (2025). The mechanism of nesprin-2 accumulation at the nucleus front during confined cell migration. Biophysical Journal, 124(12), 2056–2069.
7. Hamy, A. S., Grandal, B., Jochum, F., et al. (2025). Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort. ESMO Open, 10(5), Article 104507.
8. Simanov, G., Rocques, N., Romero, S., et al. (2024). The Arp2/3 inhibitory protein Arpin inhibits homology‐directed DNA repair. Biology of the Cell, 116(10), Article e2400073.
9. Dumas, E., Grandal Rejo, B., Gougis, P., et al. (2024). Concomitant medication, comorbidity and survival in patients with breast cancer. Nature Communications, 15(1), Article 2966.
10. Dakroub, R., Huard, S., Hajj-Younes, Y., et al. (2023). Therapeutic advantage of targeting PRMT5 in combination with chemotherapies or EGFR/HER2 inhibitors in triple-negative breast cancers. Breast Cancer: Targets and Therapy, 15, 785–799.
11. El‐Botty, R., Vacher, S., Mainguené, J., et al. (2023). HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers. Molecular Oncology, 17(10), 2017–2028.
12. Dumas, E., Grandal, B., Gougis, P., et al. (2023). Comedications at Breast Cancer diagnosis impact overall survival: results from the ADRENALINE (Atlas for DRug and brEast caNcer survivAL INtEraction) study (n= 235,368). Cancer Research, 83(5), Article 4321.
13. Dumas, E., Grandal, B., Gougis, P., et al. (2023). Abstract P3-07-06: Comedications at Breast Cancer diagnosis impact overall survival: results from the ADRENALINE (Atlas for DRug and brEast caNcer survivAL INtEraction) study. Cancer Research, 83(5_Supplement), P3-07-06-P3-07-06.
14. Suresh, S., Vinet, M., Dakroub, R., et al. (2022). Expression, localization and prognosis association of MEP50 in breast cancer. Cancers, 14(19), Article 4766.
15. Hamy, A. S., Kassara, A., Hocini, H., et al. (2022). Impact of comedications on pCR rates and relapse in breast cancer. Analysis of the Saint-Louis observational cohort. Cancer Research, 82(12_Supplement), 3348–3348.
16. Dumas, E., Grandal, B., Laot, L., et al. (2022). ADRENALINE, an atlas for drug and breast cancer survival interaction: Comedications at diagnosis and impact on breast cancer mortality of the French breast cancer cohort (n = 235,368). Cancer Research, 82(12_Supplement), 4101–4101.
17. Nguyen Van Long, F., Lardy-Cleaud, A., Carène, D., et al. (2022). Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer. BMC Cancer, 22(1), Article 526.
18. Suresh, S., Huard, S., Brisson, A., et al. (2022). PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer. Cancers, 14(2), Article 306.
19. Suresh, S., Huard, S., & Dubois, T. (2021). CARM1/PRMT4: making its mark beyond its function as a transcriptional coactivator. Trends in Cell Biology, 31(5), 402–417.
20. Marcel, V., Kielbassa, J., Marchand, V., et al. (2021). Erratum: Ribosomal RNA 2'O-methylation as a novel layer of inter-tumour heterogeneity in breast cancer. NAR Cancer, 3(1), Article zcab006.

Profile Details
https://institut-curie.org/person/thierry-dubois
https://scholar.google.com/citations?user=iQX3jqMAAAAJ&hl=fr
https://www.researchgate.net/profile/Thierry-Dubois

WOS ResearcherID: D-2852-2017